Talon Therapeutics to Host a Conference Call to Report 2012 Financial Results and Business Update on April 1, 2013

Tue Mar 19, 2013 9:00am EDT

* Reuters is not responsible for the content in this press release.


SOUTH SAN FRANCISCO, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc.
(OTCQB:TLON) will host a conference call on Monday, April 1, 2013 at 9:00AM PDT, to discuss 2012
financial results and provide a business update.

 Conference call details:                                                                                                                                  
 Date:                       Monday, April 1, 2013                                                                                                         
 Time:                       12:00PM EDT / 9:00AM PDT                                                                                                      
 Dial-in (U.S. and Canada):  (877) 681 - 1326                                                                                                              
 Dial-in (International):    (708) 290 - 1158                                                                                                              
 Web cast:                   www.talontx.com http://www.globenewswire.com/newsroom/ctr?d=10025278&l=1&a=www.talontx.com&u=http%3A%2F%2Fwww.talontx.com%2F  

An archived version of the webcast will also be available via the company's website following the

About Talon Therapeutics

Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical
opportunities, efficiently and expertly leading product candidates through clinical development,
and transferring value to patients, patient care providers, shareholders, corporate partners, and

Additional information on Talon Therapeutics can be found at www.talontx.com

The Talon Therapeutics, Inc. logo is available at:

CONTACT: Talon Therapeutics, Inc.
         Investor & Media Contacts:
         Investor Relations Team
         (650) 588-6641

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.